Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Krüger N, Tabori S, Schäkel K. Eyerich K, et al. Among authors: personke y. JAMA Dermatol. 2024 Sep 1;160(9):953-963. doi: 10.1001/jamadermatol.2024.2463. JAMA Dermatol. 2024. PMID: 39083288 Free PMC article. Clinical Trial.
Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.
Gerdes S, Hoffmann M, Asadullah K, Korge B, Mortazawi D, Krüger N, Personke Y, Tabori S, Gomez M, Wegner S, Kreimendahl F, Taut F, Sticherling M. Gerdes S, et al. Among authors: personke y. J Eur Acad Dermatol Venereol. 2023 Jul 18. doi: 10.1111/jdv.19296. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37462295
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: personke y. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S, Asadullah K, Hoffmann M, Korge B, Mortazawi D, Wegner S, Personke Y, Gomez M, Sticherling M. Gerdes S, et al. Among authors: personke y. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1568-1577. doi: 10.1111/jdv.18218. Epub 2022 May 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35569014
Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, Personke Y, Gomez M, Sticherling M. Gerdes S, et al. Among authors: personke y. J Dermatol. 2021 Dec;48(12):1854-1862. doi: 10.1111/1346-8138.16128. Epub 2021 Sep 12. J Dermatol. 2021. PMID: 34510527